Erratum: Plasma Pentraxin 3 Is Closely Associated with Peripheral Arterial Disease in Hemodialysis Patients and Predicts Clinical Outcome: A 6-Year Follow-Up

<b><i>Background:</i></b> The aim of this study is to investigate the value of plasma PTX3 level for assessing peripheral artery disease (PAD) and clinical outcome in hemodialysis (HD) patients. <b><i>Methods:</i></b> The ankle-brachial index (ABI) was measured in HD patients. PTX3 levels in 116 HD patients were measured by ELISA. <b><i>Results:</i></b> Overall, 116 HD patients were enrolled; 21 (18%) patients had PAD. Using the ROC curve analysis for PAD, PTX3 (cut-off value 4.06 ng/ml, AUC 0.901, p &lt; 0.0001) showed a significantly better positive predictive value than hsCRP (cut-off value 3.33 ng/ml, AUC 0.640, p &lt; 0.05). During follow-up (mean 57 ± 26 months), 40 deaths (34%) occurred. Kaplan-Meier analysis found that those patients with elevated PTX3 had a significantly poor outcome (p &lt; 0.0001), and Cox analysis further confirmed that PTX3 was an independent predictor of overall mortality (HR, 1.105, p = 0.03). For prediction of overall mortality, the AUC for PTX3 (cut-off value 3.22 ng/ml, AUC 0.690, p &lt; 0.0001) was close to hsCRP (cut-off value 5.84 ng/ml, AUC 0.620, p &lt; 0.001). <b><i>Conclusions:</i></b> For the prediction of PAD in HD patients, the diagnostic sensitivity and specificity of PTX3 were higher than those of hsCRP. Furthermore, PTX3 was also a predictor of all-cause mortality in HD patients. PTX3 may be considered a novel biomarker of inflammation in HD patients.

**背景**：本研究旨在探讨血浆PTX3水平在评估血液透析（Hemodialysis, HD）患者外周动脉疾病（Peripheral Artery Disease, PAD）及临床预后中的应用价值。**方法**：对HD患者实施踝肱指数（Ankle-Brachial Index, ABI）检测；采用酶联免疫吸附试验（Enzyme-Linked Immunosorbent Assay, ELISA）检测116例HD患者的血浆PTX3水平。**结果**：本研究共纳入116例HD患者，其中21例（18%）合并PAD。针对PAD的受试者工作特征曲线（Receiver Operating Characteristic curve, ROC）分析显示，PTX3的截断值为4.06 ng/ml，曲线下面积（Area Under the Curve, AUC）为0.901（p < 0.0001），其阳性预测值显著优于高敏C反应蛋白（high-sensitivity C-reactive protein, hsCRP）（hsCRP截断值为3.33 ng/ml，AUC为0.640，p < 0.05）。随访周期平均为57±26个月，期间共发生40例死亡事件，占比34%。卡普兰-迈耶（Kaplan-Meier）分析显示，PTX3水平升高的患者临床预后显著更差（p < 0.0001）；Cox回归分析进一步证实，PTX3是全因死亡率的独立预测因子（风险比（Hazard Ratio, HR）=1.105，p=0.03）。在全因死亡率预测方面，PTX3的AUC为0.690（截断值3.22 ng/ml，p < 0.0001），其预测效能与hsCRP（截断值5.84 ng/ml，AUC为0.620，p < 0.001）相近。**结论**：针对HD患者的PAD预测，PTX3的诊断灵敏度与特异度均高于hsCRP。此外，PTX3亦可作为HD患者全因死亡率的预测因子，或可成为HD患者炎症状态的新型生物标志物。